Sciwind Biosciences APAC CO Pty. Ltd. Report issue

For profit Phase 2
Founded: Hangzhou China (2017)

Organization Overview

First Clinical Trial
2020
NCT04389775
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Hangzhou Sciwind Biosciences Co., Ltd. | Sciwind Biosciences APAC CO Pty. Ltd. | Sciwind Biosciences USA Co., Ltd | Sciwind Biosciences USA Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (3)

liraglutide (victoza) (1 trial)

xw001 (1 trial)

xw003 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 1)

Diabetes Mellitus, Type 2 (Phase 1)

Fatty Liver (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3